Olveira, A, Crespo, J, Samaniego, LI, Gallego-Durán, R, Panero, JLC, Aller, R, Soria, A, Gómez-Camarero, J, Martin-Mateos, R, Benlloch, S, Pericàs, JM, Morillas, RM, Bernal, V, Diago, M, Turnes, J, Poca, M, Lo Iacono, O, Escudero-García, D, Andrade, RJ, Rosales-Zábal, JM, Jorquera, F, Fernández-Rodríguez, C, Guerra, MH, Romero-Gómez, M, Herrojo, JA. Validation of proposed non-invasive criteria for resmetirom treatment in metabolic-associated liver disease in clinical practice. JOURNAL OF HEPATOLOGY. 2025; 82DOI:. PMID:. IF:33.000(Q1/1D).

Guerrero, A, Verdyguer, MR, Martínez, SM, Campos, M, Sogbe, M, Fajes, JLH, Pascual, S, Cuyas, B, Minguez, B, Lamas-Alvarez, S, Fortea, J, Lopez-Fando, MPV, Lozano, MD, Gómez-Rubio, M, Perelló, C, Gutiérrez, ML, Romero-Gutiérrez, M, Mancebo, A, Planas, JMM, Téllez, L, Panero, JLC, De la Poza, G, Piqueras, B, Puente, A, Varela, M, Genesca, J, Alvarado-Tapias, E, D'Avola, D, Matilla, A, Sangro, B, Reig, M, Lledó, JL, Albillos, A. Prognostic influence of clinically significant portal hypertension in patients with compensated cirrhosis and hepatocellular carcinoma receiving systemic therapy: The HIPERIA study. JOURNAL OF HEPATOLOGY. 2025; 82DOI:. PMID:. IF:33.000(Q1/1D).

Alabau, BB, Plessier, A, Sanchez, FB, Payancé, A, Ballester, TG, Elkrief, L, Sánchez-Lorenzo, A, Larrue, H, Donate, J, Vidal-González, J, Praktiknjo, M, González-Alayón, C, Tripathi, D, Fortea, J, Gioia, S, alvarez-Navascués, C, Raevens, S, Herrera, EL, Protopapas, A, Nery, FGC, Artaza, T, La Mura, V, Baiges, A, Ollivier-Hourmand, I, Darnell, A, Zekrini, K, Belmonte, E, García-Criado, MA, Turon, F, Hernández-Gea, V, Verhelst, X, Riggio, O, Puente, A, Simon-Talero, M, Téllez, L, Bureau, C, Alvarado-Tapias, E, Ballester, MP, Rautou, PE, García-Pagán, JC. Development of portal hypertension after non-cirrhotic non-tumoral recent portal vein thrombosis (RPVT). A long-term follow-up study. JOURNAL OF HEPATOLOGY. 2025; 82DOI:. PMID:. IF:33.000(Q1/1D).

Younossi, Z, de Avila, L, Petta, S, Nakajima, A, Crespo, J, Kim, SU, Castera, L, Zheng, MH, Tsochatzis, E, Trivikrama, SK, Shalimar, S, Alswat, KA, Yilmaz, Y, Yu, ML, Francque, S, Chan, WK, Fernández, MIC, Treeprasertsuk, S, Duseja, AK, Gadano, A, Oliveira, CP, Arab, JP, Papatheodoridis, G, Diaz, LA, Sebastiani, G, D'Ambrosio, R, Valsan, A, Khalid, A, Holleboom, AG, El-Kassas, M, Pugliese, N, Singal, AK, Pearlman, B, Choudhary, NS, Cordie, A, Gunn, N, Caussy, C, Mauricio, D, Kawaguchi, T, Russo, FP, Venu, A, Hagström, H, Alkhouri, N, Ananchuensook, P, Mohan, L, Fan, JA, Roberts, S, Wong, VWS, Dunn, W, Ekstedt, M, Goh, GBB, Pessoa, M, Lampertico, P, Pennisi, G, Shang, Y, Liu, WY, Lee, HW, Kobayashi, T, Kakizaki, S, Iruzubieta, P, Nadeem, R, Cinque, F, Neonaki, A, Zoncapè, M, Yang, RX, Song, SJ, Dunn, N, Gadi, Z, Yeh, ML, Teh, KKJ, Mahadeva, S, Fabian, LG, Almohsen, A, Leite, N, Vessby, J, Xie, CC, Friend, E, Poca, M, Segrestin, B, Arrese, M, Lam, B, Racila, A, Alqahtani, S, Stepanova, M. Metabolic dysfunction-and alcohol-associated steatotic liver disease is associated with higher risk of advanced fibrosis and mortality than metabolic dysfunction-associated steatotic liver disease: data from a large global biopsy-proven cohort. JOURNAL OF HEPATOLOGY. 2025; 82DOI:. PMID:. IF:33.000(Q1/1D).